William Rice - Aptose Biosciences Chairman, CEO and Pres
| APS Stock | CAD 0.27 0.07 20.59% |
Chairman
Dr. William G. Rice, Ph.D., was appointed as Chairman of the Board, President, Chief Executive Officer of Aptose Biosciences Inc., with effect from October 28, 2013. Prior to joining Lorus, Dr. Rice served as the President, Chief Executive Officer and Chairman of the board of Cylene Pharmaceuticals, Inc., a private biotechnology company . Prior to Cylene, Dr. Rice was the founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. He also served as Senior Scientist and Head of the Drug Mechanism Laboratory at the National Cancer Institute Frederick Cancer Research and Development Center, and served as a faculty member in the division of Pediatric Hematology and Oncology at Emory University School of Medicine since 2013.
| Age | 65 |
| Tenure | 11 years |
| Professional Marks | Ph.D |
| Address | 251 Consumers Road, Toronto, ON, Canada, M2J 4R3 |
| Phone | 647 479 9828 |
| Web | https://www.aptose.com |
William Rice Latest Insider Activity
Tracking and analyzing the buying and selling activities of William Rice against Aptose Biosciences stock is an integral part of due diligence when investing in Aptose Biosciences. William Rice insider activity provides valuable insight into whether Aptose Biosciences is net buyers or sellers over its current business cycle. Note, Aptose Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Aptose Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
William Rice over six months ago Acquisition by William Rice of 70000 shares of Aptose Biosciences subject to Rule 16b-3 |
Aptose Biosciences Management Efficiency
The company has return on total asset (ROA) of (1.3629) % which means that it has lost $1.3629 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (6.9413) %, meaning that it generated substantial loss on money invested by shareholders. Aptose Biosciences' management efficiency ratios could be used to measure how well Aptose Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Aptose Biosciences' Return On Capital Employed is very stable compared to the past year. As of the 23rd of November 2024, Return On Equity is likely to grow to 18.53, though Return On Tangible Assets are likely to grow to (3.75). At this time, Aptose Biosciences' Non Current Assets Total are very stable compared to the past year. As of the 23rd of November 2024, Fixed Asset Turnover is likely to grow to 0.84, while Total Assets are likely to drop about 12.3 M.Similar Executives
| Found 1 records | CHAIRMAN Age | ||
| Wayne Pisano | Oncolytics Biotech | 64 | |
Management Performance
| Return On Equity | -6.94 | ||||
| Return On Asset | -1.36 |
Aptose Biosciences Leadership Team
Elected by the shareholders, the Aptose Biosciences' board of directors comprises two types of representatives: Aptose Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aptose. The board's role is to monitor Aptose Biosciences' management team and ensure that shareholders' interests are well served. Aptose Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aptose Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Philippe Ledru, Senior Officer | ||
| Fletcher Payne, CFO, VP | ||
| Janet CA, VP Fin | ||
| Rafael MD, Senior Officer | ||
| Roger BSc, Vice Operations | ||
| Marc Wiles, Senior Affairs | ||
| Brooks MBA, VP Controller | ||
| William Rice, Chairman, CEO and Pres |
Aptose Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aptose Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.94 | ||||
| Return On Asset | -1.36 | ||||
| Current Valuation | (3.86 M) | ||||
| Shares Outstanding | 19.52 M | ||||
| Shares Owned By Insiders | 15.87 % | ||||
| Shares Owned By Institutions | 16.68 % | ||||
| Number Of Shares Shorted | 2.25 K | ||||
| Price To Earning | (1.85) X | ||||
| Price To Book | 68.22 X | ||||
| EBITDA | (52.27 M) |
Pair Trading with Aptose Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptose Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptose Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving against Aptose Stock
| 0.47 | WMT | Walmart Inc CDR | PairCorr |
| 0.36 | TSLA | Tesla Inc CDR | PairCorr |
| 0.31 | BRK | Berkshire Hathaway CDR | PairCorr |
The ability to find closely correlated positions to Aptose Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptose Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptose Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptose Biosciences to buy it.
The correlation of Aptose Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptose Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptose Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aptose Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.